Beit Jala Pharmaceutical Company (PEX:BJP)

PEX:BJP Income Statement

Financials in millions JOD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	12.78	9.66	9.61	10.77	9.76
Revenue Growth (YoY)	32.28%	0.54%	-10.73%	10.37%	12.26%
Cost of Revenue	7.8	6.48	6.15	6.75	6.96
Gross Profit	4.98	3.19	3.46	4.02	2.79
Selling, General & Admin	1.66	1.26	1.3	1.66	1.69
Operating Expenses	1.66	1.26	1.3	1.66	1.69
Operating Income	3.32	1.92	2.16	2.35	1.11
Interest Expense	-0.05	-0.11	-0.11	-0.12	-0.09
Currency Exchange Gain (Loss)	-0.27	0.06	-0.1	0.12	0.03
Other Non Operating Income (Expenses)	0.01	-	0.01	0.01	0.01
Pretax Income	3	1.87	1.96	2.36	1.05
Income Tax Expense	0.27	0.12	0.12	0.38	0.18
Net Income	2.73	1.76	1.84	1.98	0.87
Net Income to Common	2.73	1.76	1.84	1.98	0.87
Net Income Growth	55.69%	-4.42%	-7.26%	127.43%	16.87%
Shares Outstanding (Basic)	7	7	7	7	7
Shares Outstanding (Diluted)	7	7	7	7	7
Shares Change (YoY)	-0.01%	-	-	-	-
EPS (Basic)	0.39	0.25	0.26	0.28	0.12
EPS (Diluted)	0.39	0.25	0.26	0.28	0.12
EPS Growth	55.70%	-4.42%	-7.26%	127.43%	16.87%
Free Cash Flow	0.15	0.22	0.67	2.81	0.27
Free Cash Flow Per Share	0.02	0.03	0.10	0.40	0.04
Dividend Per Share	-	0.120	0.100	0.100	0.100
Dividend Growth	-	20.00%	-	-	-
Gross Margin	38.96%	32.99%	36.00%	37.31%	28.63%
Operating Margin	25.99%	19.91%	22.45%	21.87%	11.35%
Profit Margin	21.39%	18.17%	19.11%	18.40%	8.93%
Free Cash Flow Margin	1.14%	2.26%	6.97%	26.14%	2.75%
EBITDA	6.29	2.6	3.26	3.31	2.12
EBITDA Margin	49.24%	26.95%	33.90%	30.70%	21.69%
D&A For EBITDA	2.97	0.68	1.1	0.95	1.01
EBIT	3.32	1.92	2.16	2.35	1.11
EBIT Margin	25.99%	19.91%	22.45%	21.87%	11.35%
Effective Tax Rate	8.87%	6.18%	6.29%	16.22%	17.21%
Advertising Expenses	-	0.03	0.04	0.08	0.07

Source: S&P Global Market Intelligence. Standard template. Financial Sources.